About this trial
During a cessation therapy for tobacco or cannabis, sleep disorders are one of the main risk factors of relapse, and a symptom of substance withdrawing. In this study, we make the hypothesis that identifying and managing potential sleep disorders during cessation treatment may contribute to maintain tobacco / cannabis abstinence on the long-term. To evaluate the impact of such intervention, we will conduct a randomised pilot study among patients consulting at two addiction prevention and care centres, for smoking or cannabis use cessation treatment. Control group will benefit of usual care (a multidisciplinary care with individual and group therapies); intervention group will benefit in addition of a systematic screening of sleep disorders, and in case of a diagnosed alteration, they will be addressed to the Chronos centre, for specific care to help them manage and reduce the consequences of their sleep disorders. Participants will be followed over a 6-month period, with visits at 1 and 3 months, to monitor smoking or cannabis cessation, and other criteria associated with their substance use or sleep.
Eligibility criteria
Qualifiers
patients over 18 years old
presenting at the participating addiction treatment centres for a smoking or cabannis use cessation therapy
who agree to participate to the study
affiliated to the French health insurance system
Disqualifiers
Patients hospitalised during the cessation therapy
Patients undergoing sleep disorders treatment
Patients participating to another study
Patients with psychotic disorders (according the DSM-5 classification)
Trial design
Treatments tested in this trial
- Screening and management of sleep disorders